Lucid Diagnostics Inc. (LUCD)
| Market Cap | 196.22M |
| Revenue (ttm) | 4.71M |
| Net Income (ttm) | -70.57M |
| Shares Out | 188.67M |
| EPS (ttm) | -0.69 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 612,901 |
| Open | 1.080 |
| Previous Close | 1.060 |
| Day's Range | 1.040 - 1.118 |
| 52-Week Range | 0.950 - 1.700 |
| Beta | 1.24 |
| Analysts | Strong Buy |
| Price Target | 4.13 (+297.12%) |
| Earnings Date | May 13, 2026 |
About LUCD
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. It focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. The company’s flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in ... [Read more]
Financial Performance
In 2025, Lucid Diagnostics's revenue was $4.71 million, an increase of 8.28% compared to the previous year's $4.35 million. Losses were -$70.57 million, 33.1% more than in 2024.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for LUCD stock is "Strong Buy." The 12-month stock price target is $4.13, which is an increase of 297.12% from the latest price.
News
Lucid Diagnostics Announces Closing of $18 Million Underwritten Offering of Common Stock
NEW YORK, April 24, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed ...
Lucid Diagnostics Announces $18 Million Underwritten Offering of Common Stock
NEW YORK, April 23, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed ...
Lucid Diagnostics to Participate in Fireside Chat at the 25th Annual Needham Virtual Healthcare Conference
NEW YORK, April 9, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed I...
PAVmed Appoints Joseph Virgilio to Lead Relaunched Medical Device Portfolio
Medtech industry veteran to oversee development and commercialization of PAVmed's current and future medical device portfolio. Octeris, Inc. subsidiary formed to advance endoscopic esophageal imaging ...
PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
PAVmed strengthened its capital structure and relaunched its medical device portfolio under new leadership Veris Health advanced strategic partnership with OSU and progressed implantable physiological...
Lucid Diagnostics Earnings Call Transcript: Q4 2025
Fourth quarter test volume and revenue grew sharply, driven by commercial execution and new VA contract. Medicare coverage is expected soon, which will significantly expand addressable market and revenue potential. Commercial payer and LBM engagement continues to progress.
Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Processed 3,664 EsoGuard ® tests and recognized 4Q25 revenue of $1.5 million Expanded EsoGuard access with U.S. Department of Veterans Affairs contract award and strengthened clinical evidence with po...
PAVmed to Hold Fourth Quarter and Full Year 2025 Business Update Conference Call and Webcast on March 30, 2026
Conference Call and Webcast at 8:30 AM ET NEW YORK, March 16, 2026 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, ...
Lucid Diagnostics to Hold Fourth Quarter and Full Year 2025 Business Update Conference Call and Webcast on March 26, 2026
Conference Call and Webcast at 8:30 AM ET NEW YORK, March 12, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diag...
PAVmed Closes Preferred Stock and Senior Secured Note Financings, Eliminating All Previously Outstanding Convertible Securities
Series D Preferred Stock offering yielded $30 million of gross proceeds and includes warrants exercisable for up to an additional $30 million upon publication of a positive draft EsoGuard Medicare loc...
Lucid Diagnostics Awarded U.S. Department of Veterans Affairs Contract for EsoGuard®
NEW YORK, Jan. 21, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed In...
Lucid Diagnostics Announces Positive Data from the Largest Reported Real-World Experience of Esophageal Precancer Detection
Report includes nearly 12,000 patients who underwent Lucid's EsoGuard® Esophageal DNA Test on samples collected using its EsoCheck® Esophageal Cell Collection Device Real-world data confirm excellent ...
Lucid Diagnostics Named a GenomeWeb 2025 Best Places to Work Top-Ranking Honoree
Recognized as the leading company in its size category in program honoring the top workplaces across the diagnostics and precision-medicine sectors NEW YORK , Nov. 20, 2025 /PRNewswire/ -- Lucid Diag...
Lucid Diagnostics to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
NEW YORK , Nov. 13, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed ...
PAVmed Provides Business Update and Reports Third Quarter 2025 Financial Results
Veris Health launched commercial phase of strategic partnership and relaunched development of implantable physiological monitor PAVmed signed letter of intent (LOI) to license groundbreaking endoscopi...
Lucid Diagnostics Earnings Call Transcript: Q3 2025
Q3 results showed stable test volumes and revenue, with strong progress toward Medicare coverage for EsoGuard following a positive CAC meeting. Cash runway was extended through 2026 after a $27 million offering, and commercial payer engagement is accelerating.
Lucid Diagnostics Provides Business Update and Reports Third Quarter 2025 Financial Results
Processed 2,841 EsoGuard® tests and recognized 3Q25 revenue of $1.2 million, ending quarter with over $47 million in proforma cash and extending runway through 2026 and well past upcoming reimbursemen...
PAVmed to Hold a Business Update Conference Call and Webcast on November 13, 2025
Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK , Oct. 30, 2025 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology ...
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 12, 2025
Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK , Oct. 29, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention me...
Lucid Diagnostics to Participate in the 2025 Maxim Growth Summit
NEW YORK , Oct. 15, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed ...
Lucid Diagnostics Appoints Healthcare Industry Veteran John R. Palumbo to Board of Directors
Growth-focused healthcare executive brings 40 years of executive leadership experience across multiple industry sectors NEW YORK , Sept. 25, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD)...
Lucid Diagnostics Appoints Danielle Scelfo as Senior Vice President, Market Access & Government Affairs
Scelfo to strengthen and scale Lucid's market access infrastructure ahead of key upcoming reimbursement milestones—including Medicare coverage for EsoGuard—and to accelerate commercial coverage expans...
Lucid Diagnostics Announces Closing of Public Offering of Common Stock
NEW YORK , Sept. 11, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed...
Lucid Diagnostics Announces Pricing of Public Offering of Common Stock
NEW YORK , Sept. 10, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVme...
Lucid Diagnostics Announces Proposed Public Offering of Common Stock
NEW YORK , Sept. 9, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed...